The UK and US have agreed to a major trade agreement that will keep no tariffs on UK medicine exports going into the American market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has pledged to increase spending on pharmaceuticals through the NHS. This pledge secures that tariffs on these crucial goods will stay at zero for a duration of three years.
This agreement follows recent threats to significantly raise duties on patented drug imports, with potential rates discussed reaching one hundred percent.
"This deal with the UK strengthens the worldwide climate for new treatments and introduces much-needed fairness to transatlantic medicine commerce," a statement noted.
Trade Impact
Drugs are one of the Britain's biggest export categories to the US, which is easily the biggest market for leading companies like GSK and AstraZeneca.
Statistics show that in the year leading up to last September, the UK exported drugs worth over eleven billion pounds to the US. This amount represented 17.4% of British export trade in that span.
"This deal secures employment, boosts investment and sets the stage for the UK to establish itself as a international leader for life sciences," the Business and Trade Secretary commented.
Key British Pledges
The agreement includes several key commitments from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it considers new therapies to be too expensive by a quarter.
- Boosted Medicine Funding: There is a target to increase total NHS spending on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The percentage drug companies must pay back to the NHS to control costs will be capped at fifteen percent. Previously, rebates exceeded 20%.
Industry Background
The deal comes amid a long-running tension between the pharmaceutical industry and the UK government over drug pricing and NHS adoption.
The disagreement were heightened by claims that US patients were charged several times more for the identical medicines than consumers in the other developed nations.
In recent months, several significant manufacturing plans in the UK have been delayed or cancelled, while substantial expansions have been pledged toward US facilities.
The Science Minister acknowledged that the NHS must invest a greater share on medicines, noting that its spending on drugs had declined as a share of its resources over the past decade.
